Compare Elastic NV (ESTC) vs Fiverr International Ltd (FVRR) Price & Performance

Elastic (ESTC) trades at $97.54, up 4.77% on the day, reflecting strong momentum as it approaches resistance near $98. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though the short-term RSI indicates potential overbought conditions. Fundamentally, the company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, projected to rise from $1.48 billion in 2025 to $1.8 billion in 2026, while net income is expected to swing from a loss to a $376 million profit, signaling improving profitability. Recent news highlights product innovations in AI and observability platforms, reinforcing its competitive edge.

The outlook for ESTC is positive, driven by earnings beats, solid revenue expansion, and strategic product launches in high-growth areas like AI and data search. Key risks include high valuation multiples, such as a P/E of 27.22 and EV/EBITDA of 496.59, which may limit upside if growth slows. Analyst consensus is strongly bullish with a 64.71% buy rating, though the average price target of $79.50 suggests caution relative to the current price. Investors should weigh the strong fundamental trajectory against valuation concerns and market volatility.

Fiverr International (FVRR) trades at $8.68, up 2.12% with bearish technical signals despite attractive valuation metrics including a P/E of 10.67 and P/S of 0.76. Recent earnings show mixed results with Q2 2026 missing estimates, while revenue growth has slowed from 2025's $431M to projected $418M in 2026. The company faces AI disruption pressures but maintains strong gross margins of 82% and positive net income.

The outlook remains cautious with analysts predominantly holding neutral ratings (76% Hold) and a $10.50 price target suggesting modest upside. Key risks include AI competition compressing freelance demand, while potential exists if Fiverr successfully adapts its platform to AI-driven market changes. Current valuation appears reasonable for patient investors despite near-term headwinds.